COMMUNIQUÉS West-GlobeNewswire

AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)
11/08/2026
AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD) Ongoing Phase 2 VacSYn study to expand to sites in USA with Investigational [...]
Modern Haus Dental's Dr. Kristy Lee Recognized as Top Dentist by Bethesda Magazine for Third Consecutive Year
11/08/2026
She has also been named a Top Dentist by Washingtonian Magazine for two consecutive years Modern Haus Dental's Dr. Kristy Lee Earns Third Consecutive Bethesda Magazine Title Chevy Chase, MARYLAND, Aug. 11, 2026 (GLOBE [...]
Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
11/08/2026
Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination study of [...]
Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update
11/08/2026
BETHESDA, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
11/08/2026
The Company expects to initiate its Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer in the fourth quarter Presented preclinical data demonstrating differentiated [...]
Vivos Therapeutics Expands Greenway Health Partnership to Deploy AI-Enabled Platform Across All Clinical and Revenue Operations
11/08/2026
Greenway analysis estimates AI-enabled automation in Nevada alone could create up to $9.0 million in potential annual value, including approximately $8.0 million from increased patient capacity and $1.0 million from [...]
Intelligent Bio Solutions Announces Completion of Method Comparison Study for the Intelligent Fingerprinting Drug Screening System
11/08/2026
All clinical data collection across the Company's FDA 510(k) clinical study program is complete; FDA submission on track for second half of 2026 NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc [...]
RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer
11/08/2026
Completion of Trial Expected in First Half 2027 With Topline Data Readout Expected Second Half 2027 MOUNTAIN VIEW, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , [...]
Conexeu to Present at 2026 Controversies & Conversations in Laser & Cosmetic Surgery Symposium on the Role of the Extracellular Matrix in Tissue Regeneration
11/08/2026
RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq: CNXU) ("Conexeu" or the "Company"), a preclinical-stage biotechnology company advancing an investigational tissue-restoration platform, [...]
Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile
11/08/2026
Findings further validate Cingulate’s Precision Timed Release™ (PTR™) platform and its trimodal drug delivery approach KANSAS CITY, Kan., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a [...]
Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
11/08/2026
Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following FDA approval Strengthened organization with new [...]
Introducing Veritas24-7™ – A New Way for Pharmaceutical Companies to Engage Physicians 24 Hours a Day
11/08/2026
Through lifelike AI personas, Veritas24-7 provides physicians with immediate 24 hours a day access to company-approved Medical Science Liaison and Sales Representative expertise through natural, face-to-face, two-way [...]
PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101
11/08/2026
PDS0301 Phase 2 clinical data in mCRC and a comprehensive review of capital allocation priorities drive strategic refocus designed to maximize long-term shareholder value PRINCETON, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE [...]
Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights
11/08/2026
Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo’s investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) Mereo and partner Ultragenyx [...]
Flyte Partners with The Nucleus Network for Inaugural Flagship Founder & Investor Event
11/08/2026
Strategic Partnership Places Flyte at the Center of One of the Nation's Premier Communities of Founders, Investors, and Operators Collaboration Reflects Flyte's Continued Commitment to Building Relationships Within the [...]
Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Compromising Drug Delivery
11/08/2026
Vancouver, Canada, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND, FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, [...]
Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy
11/08/2026
TEL AVIV, Israel, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Moody’s Ratings has upgraded Teva’s corporate credit rating to Baa3 from Ba1, an [...]
Nu-Tek BioSciences Earns EcoVadis Bronze Rating for Third Consecutive Year, Strengthening Sustainable Biopharmaceutical Supplier Status
11/08/2026
EcoVadis recognition reinforces Nu-Tek's sustained investment in the sustainable manufacturing of animal-origin-free cell culture media nutrients and fermentation ingredients. MINNETONKA, Minn., Aug. 11, 2026 (GLOBE [...]
Nu-Tek BioSciences obtient la Médaille de bronze décernée par EcoVadis pour la troisième année consécutive, consolidant ainsi son statut de fournisseur biopharmaceutique respectueux de l’environnement
11/08/2026
Cette distinction d’EcoVadis vient renforcer l’engagement continu de Nu-Tek en faveur de la fabrication durable de nutriments pour milieux de culture cellulaire et d’ingrédients de fermentation sans composants d’origine [...]

Pages